Black survivors of multiple myeloma say the latest developments in treatment give them hope even as federal research cuts ...
Exploring Teclistamab’s Potential in Combination Therapy for Multiple Myeloma: Marc S. Raab, MD, PhD
Marc S. Raab, MD, PhD, discusses the different ways that combination therapy that includes teclistamab can benefit patients ...
Multiple myeloma survivor Ronald D. Chin, one of CURE’s contributing bloggers, shared a bit of his blood cancer journey in a ...
The FDA has approved Blenrep with BVd as a third-line treatment for relapsed or refractory multiple myeloma.
In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...
MedPage Today on MSN
CAR-T Drug for Myeloma Hit With New Boxed Warning
Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...
Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent ...
GlobalData on MSN
GSK’s Blenrep gains FDA approval for myeloma treatment
The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.
The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...
GSK has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) in ...
The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback